Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1, Open-label, Dose-escalation Trial with CD38-SADA:177 Lu-DOTA Drug Complex in Subjects with Relapsed or Refractory Non-Hodgkin Lymphoma

Next Previous
Search
Trial Profile

Phase 1, Open-label, Dose-escalation Trial with CD38-SADA:177 Lu-DOTA Drug Complex in Subjects with Relapsed or Refractory Non-Hodgkin Lymphoma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CD-38-SADA (Primary) ; Radiopharmaceuticals
  • Indications B-cell lymphoma; Non-Hodgkin's lymphoma; T-cell lymphoma
  • Focus Adverse reactions; First in man
  • Acronyms Study 1201; Trial 1201
  • Sponsors Y-mAbs Therapeutics

    • Most Recent Events

    • 27 Jan 2025 Planned initiation date (estimated date of first participant enrollment) changed from 1 Dec 2024 to 1 Feb 2025.
    • 10 Jan 2025 According to a Y-mAbs Therapeutics media release, company expects to dose the first non-Hodgkin Lymphoma (NHL) patient in Study 1201 in the first quarter of 2025.
    • 10 Jan 2025 According to a Y-mAbs Therapeutics media release, the company announces that to date, six sites have been selected, and three sites have been activated

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top